Table I.
Variable | Viral (n=108) | Non-viral (n=130) | P-value |
---|---|---|---|
Gender (%) | <0.001 | ||
Male | 72 (66.7) | 51 (39.2) | |
Female | 36 (33.3) | 79 (60.8) | |
Age, mean years±SD | 35.1±15.8 | 38.3±19.3 | 0.186 |
Type (%) | <0.001 | ||
ALF | 46 (42.6) | 27 (20.8) | |
SALF | 62 (57.4) | 103 (79.2) | |
Coma grade (%) | 0.004 | ||
0 | 45 (41.7) | 90 (69.2) | |
1 | 0 (0.0) | 1 (0.8) | |
2 | 21 (19.4) | 16 (12.3) | |
3 | 27 (25.0) | 18 (13.8) | |
4 | 12 (11.1) | 8 (6.2) | |
Steroid use | <0.001 | ||
Total number of patients (%) | 37 (34.3) | 18 (13.8) | |
Daily Dex dose, mg/d (range) | 10 (5–20) | 10 (5–30) | |
Days of steroid use, mg/d (range) | 5 (1–90) | 5 (1–60) | |
Mean MELD | 31.3±6.2 | 30.2±6.5 | 0.162 |
Laboratory values | |||
ALT, IU/l | 1428±1637 | 591±740 | <0.001 |
AST, IU/l | 1229±1745 | 643±938 | 0.001 |
T-Bil, mg/dl | 21.4±10.3 | 24.2±11.2 | 0.050 |
Cr, mg/dl | 1.22±0.59 | 1.20±0.59 | 0.822 |
INR | 3.35±1.70 | 3.08±2.02 | 0.268 |
Data are expressed as number of patients in each group, unless indicated otherwise. SD, standard deviation; ALF, acute liver failure; SALF, subacute liver failure; Dex, dexamethasone; MELD, Model for End-stage Liver Disease; ALT, alanine aminotransferase; AST, aspartate aminotransferase; T-Bil, serum total bilirubin; Cr, creatinine; INR, international normalized ratio.